The peroxisome proliferator-activated receptor α agonist, AZD4619, induces alanine aminotransferase-1 gene and protein expression in human, but not in rat hepatocytes: Correlation with serum ALT levels

Thulin,Petra; Bamberg,Krister; Buler,Marcin; Dahl,Björn; Glinghammar,Björn

doi:10.3892/ijmm.2016.2681

The peroxisome proliferator-activated receptor α agonist, AZD4619, induces alanine aminotransferase-1 gene and protein expression in human, but not in rat hepatocytes: Correlation with serum ALT levels

Authors:
- Petra Thulin
- Krister Bamberg
- Marcin Buler
- Björn Dahl
- Björn Glinghammar
View Affiliations

Affiliations: Drug Safety and Metabolism, AstraZeneca, 43183 Mölndal, Sweden, Bioscience, AstraZeneca, 43183 Mölndal, Sweden
Published online on: July 14, 2016 https://doi.org/10.3892/ijmm.2016.2681
Pages: 961-968

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alanine aminotransferase (ALT) in serum is the standard biomarker for liver injury. We have previously described a clinical trial with a novel selective peroxisome proliferator-activated receptor α (PPARα) agonist (AZD4619), which unexpectedly caused increased serum levels of ALT in treated individuals without any other evidence of liver injury. We pinpointed a plausible mechanism through which AZD4619 could increase serum ALT levels; namely through the PPARα-specific activation of the human ALT1 gene at the transcriptional level. In the present study, we present data from the preceding rat toxicity study, demonstrating that AZD4619 had no effect on rat serum ALT activity levels, and further experiments were performed to elucidate the mechanisms responsible for this species-related difference. Our results revealed that AZD4619 increased ALT1 protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. Cloning of the human and rat ALT1 promoters into luciferase vectors confirmed that AZD4619 induced only the human, but not the rat ALT1 gene promoter in a dose-dependent manner. In PPARα-GAL4 reporter gene assays, AZD4619 was >100-fold more potent on the human vs. rat PPARα levels, explaining the differences in induction of the ALT1 gene between the species at the concentration range tested. These data demonstrate the usefulness of the human and rat ALT1 reporter gene assays for testing future drug candidates at the preclinical stage. In drug discovery projects, these assays elucidate whether elevations in ALT levels observed in vivo or in the clinic are due to metabolic effects rather than a toxic event in the liver.

View Figures

View References

1	Karmen A, Wroblewski F and Ladue JS: Transaminase activity in human blood. J Clin Invest. 34:126–131. 1955. View Article : Google Scholar : PubMed/NCBI
2	Ladue JS and Wroblewski F: The significance of the serum glutamic oxalacetic transaminase activity following acute myocardial infarction. Circulation. 11:871–877. 1955. View Article : Google Scholar : PubMed/NCBI
3	Lindena J, Sommerfeld U, Höpfel C and Trautschold I: Catalytic enzyme activity concentration in tissues of man, dog, rabbit, guinea pig, rat and mouse. Approach to a quantitative diagnostic enzymology, III. Communication. J Clin Chem Clin Biochem. 24:35–47. 1986.PubMed/NCBI
4	Yang RZ, Blaileanu G, Hansen BC, Shuldiner AR and Gong DW: cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase. Genomics. 79:445–450. 2002. View Article : Google Scholar : PubMed/NCBI
5	Sohocki MM, Sullivan LS, Harrison WR, Sodergren EJ, Elder FF, Weinstock G, Tanase S and Daiger SP: Human glutamate pyruvate transaminase (GPT): Localization to 8q24.3, cDNA and genomic sequences, and polymorphic sites. Genomics. 40:247–252. 1997. View Article : Google Scholar : PubMed/NCBI
6	Lindblom P, Rafter I, Copley C, Andersson U, Hedberg JJ, Berg AL, Samuelsson A, Hellmold H, Cotgreave I and Glinghammar B: Isoforms of alanine aminotransferases in human tissues and serum–differential tissue expression using novel antibodies. Arch Biochem Biophys. 466:66–77. 2007. View Article : Google Scholar : PubMed/NCBI
7	Miyazaki M, Rosenblum JS, Kasahara Y, Nakagawa I and Patricelli MP: Determination of enzymatic source of alanine aminotransferase activity in serum from dogs with liver injury. J Pharmacol Toxicol Methods. 60:307–315. 2009. View Article : Google Scholar : PubMed/NCBI
8	O'Brien PJ, Slaughter MR, Polley SR and Kramer K: Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab Anim. 36:313–321. 2002. View Article : Google Scholar : PubMed/NCBI
9	Reagan WJ, Yang RZ, Park S, Goldstein R, Brees D and Gong DW: Metabolic adaptive ALT isoenzyme response in livers of C57/BL6 mice treated with dexamethasone. Toxicol Pathol. 40:1117–1127. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kobayashi A, Suzuki Y, Kuno H, Sugai S, Sakakibara H and Shimoi K: Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. J Toxicol Sci. 34:377–387. 2009. View Article : Google Scholar : PubMed/NCBI
11	Blane GF: Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med. 83:26–36. 1987. View Article : Google Scholar : PubMed/NCBI
12	Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T and Barouki R: Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol Lett. 98:13–23. 1998. View Article : Google Scholar : PubMed/NCBI
13	Thulin P, Rafter I, Stockling K, Tomkiewicz C, Norjavaara E, Aggerbeck M, Hellmold H, Ehrenborg E, Andersson U, Cotgreave I and Glinghammar B: PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol Appl Pharmacol. 231:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
14	Ljung B, Bamberg K, Dahllof B, Kjellstedt A, Oakes ND, Ostling J, Svensson L and Camejo G: AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res. 43:1855–1863. 2002. View Article : Google Scholar : PubMed/NCBI
15	Ovcharenko I, Nobrega MA, Loots GG and Stubbs L: ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res. 32:W280–W286. 2004. View Article : Google Scholar : PubMed/NCBI
16	Ovcharenko I, Loots GG, Hardison RC, Miller W and Stubbs L: zPicture: Dynamic alignment and visualization tool for analyzing conservation profiles. Genome Res. 14:472–477. 2004. View Article : Google Scholar : PubMed/NCBI
17	Juge-Aubry C, Pernin A, Favez T, Burger AG, Wahli W, Meier CA and Desvergne B: DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J Biol Chem. 272:25252–25259. 1997. View Article : Google Scholar : PubMed/NCBI
18	Caplan S, Yu J, Chen P, Sabio M and Boettcher B: Comparison of ligand-binding affinities in the human, mouse and hamster PPAR[alpha] ligand-binding domains with PPAR[alpha] and PPAR[alpha]/[gamma] dual agonists. 64th Scientific Sessions(Category: Clinical Therapeutics/New Technology - Pharmacologic Treatment of Diabetes or its Complications). American Diabetes Association; pp. p5092004
19	Balfour JA, McTavish D and Heel RC: Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 40:260–290. 1990. View Article : Google Scholar : PubMed/NCBI
20	Tomkiewicz C, Muzeau F, Edgar AD, Barouki R and Aggerbeck M: Opposite regulation of the rat and human cytosolic aspartate aminotransferase genes by fibrates. Biochem Pharmacol. 67:213–225. 2004. View Article : Google Scholar
21	Sookoian S and Pirola CJ: Liver enzymes, metabolomics and genome-wide association studies: From systems biology to the personalized medicine. World J Gastroenterol. 21:711–725. 2015.PubMed/NCBI
22	Jackson ER, Kilroy C, Joslin DL, Schomaker SJ, Pruimboom-Brees I and Amacher DE: The early effects of short-term dexamethasone administration on hepatic and serum alanine aminotransferase in the rat. Drug Chem Toxicol. 31:427–445. 2008. View Article : Google Scholar : PubMed/NCBI
23	Liu R, Pan X and Whitington PF: Increased hepatic expression is a major determinant of serum alanine aminotransferase elevation in mice with nonalcoholic steatohepatitis. Liver Int. 29:337–343. 2009. View Article : Google Scholar